$RDHL 1H26 Highlights: Strategic portfolio reset - $12M acquisition of Rebyota and Clenpiq rights ($37.5 million 2025 net sales) funded by $18M Talicia sale. Stronger, improved liquidity, growth opportunities & potential for new products. #RDHL PR:
$RDHL transformational acquisition of commercialization rights to @ferring’s Rebyota® + Clenpiq®, $37.5m 2025 sales, for $12m upfront payment, fully funded by the $18m Talicia divestment - creates stronger liquidity position & growth catalyst. #RDHL PR:
$RDHL divests #Talicia to Apotex ($APTX) for $18m + up to $35m in potential add on payments to fuel strategic growth opportunities - execution of a major step on a strategic roadmap to fundamentally reposition #RDHL's commercial business. Full PR:
$RDHL announces closing of up to $19.4M private placement ($6M upfront with up to $13.4M of potential proceeds) expected to strenghten liquidity & support potential transformative revenue generating acquisitions. #RDHL PR:
